Form 8-K - Current report:
SEC Accession No. 0001493152-24-020101
Filing Date
2024-05-16
Accepted
2024-05-16 06:05:28
Documents
14
Period of Report
2024-05-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 26951
2 ex10-1.htm EX-10.1 17087
  Complete submission text file 0001493152-24-020101.txt   216507

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ppcb-20240510.xsd EX-101.SCH 3012
4 XBRL LABEL FILE ppcb-20240510_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE ppcb-20240510_pre.xml EX-101.PRE 22357
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3334
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 330662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 000-54878 | Film No.: 24953468
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)